Citations

Clear

499 citation(s) found for "Tracy, PB".

Recovery Model Implementation for a Medical/Geriatric Psychiatric Unit to Decrease Restraint and Seclusion Episodes: A Quality Improvement Project
Ayres, Sara , Tracy, Mary Fran , Ayres, Sara

Mayo Clinic

Journal of the American Psychiatric Nurses Association | October 15, 2021 | Volume: 27 | Issue: 5 | Pages: 355-360

10.1177/10783903211048449 | PMID 34651520 Get It

Introduction: In inpatient behavioral health units, a long-standing behavioral management controversy has been whether to physically restrain or seclude patients. The rate of restraint use at the institution underperformed compared with the national average, which led to the project implementation. Aims: This quality improvement project’s objective was to decrease restraint and seclusion use, improve quality of care, and decrease cost through implementation of recovery model principles. Method: Implementation started in October 2019 on a 14-bed inpatient medical/geriatric psychiatric unit with 38 psychiatric RNs at a large academic medical center. The project was a pre–post implementation design with interventions consisting of staff education, RN language observation, and orientation toolkit development. Changes in staff knowledge were measured by Recovery Knowledge Inventory surveys at baseline, 1 week posteducation, and 4 months posteducation. Restraint and seclusion use data were analyzed 3 months preimplementation and 3 months postimplementation. Results: Staff knowledge of the recovery model increased from baseline to 1 week postimplementation in all four survey domains (range = 6% to 9% improvement). While improvements were maintained in two survey domains, two domains of staff knowledge showed slight declines (1% to 2% decline in scores) 4 months postintervention. Restraint use decreased 73.1% and seclusion use decreased 16.3% from pre to postintervention. Conclusion: Implementation of recovery model principles can decrease restraint and seclusion episodes, which increases quality and decreases cost to the organization.
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Valent, Peter , Hartmann, Karin , Schwaab, Juliana , Carter, Melody C. , Elberink, Hanneke Oude , Butterfield, Joseph H. , Üstün, Celalettin , Bonadonna, Patrizia , Sotlar, Karl , Jawhar, Mohamad , Siebenhaar, Frank , Broesby‐Olsen, Sigurd , Yavuz, Selim , Zanotti, Roberta , Nedoszytko, Bogusław , Hoermann, Gregor , Radia, Deepti , Sperr, Wolfgang R. , Schwartz, Lawrence B. , Reiter, Andreas , Arock, Michel , Horny, Hans‐Peter, Metcalfe, Dean D. , Sperr, Wolfgang , Valent, Peter , Arock, Michel , Akin, Cem , Álvarez‐Twöse, Iván , Brockow, Knut , Hermine, Olivier , Niedoszytko, Marek , Lyons, Jonathan J. , George, Tracy I. , Greiner, Georg , Bonadonna, Patrizia , Nilsson, Gunnar P. , Lange, Magdalena , Castells, Mariana , Muñoz‐González, Javier I. , Triggiani, Massimo , Kluin‐Nelemans, Hanneke C. , Galli, Stephen Joseph , Órfão, Alberto , Gotlib, Jason

Mayo Clinic

HemaSphere | October 14, 2021 | Volume: 5 | Issue: 11 | Pages: e646

10.1097/hs9.0000000000000646 | PMID 34901755 Get It

Mastocytosis is a hematologic neoplasm characterized by expansion and focal accumulation of neoplastic mast cells (MC) in diverse organs, including the skin, bone marrow (BM), spleen, liver, and gastrointestinal tract. The World Health Organization classification divides the disease into prognostically distinct variants of cutaneous mastocytosis (CM) and systemic mastocytosis (SM). Although this classification remains valid, recent developments in the field and the advent of new diagnostic and prognostic parameters created a need to update and refine definitions and diagnostic criteria in MC neoplasms. In addition, MC activation syndromes (MCAS) and genetic features predisposing to SM and MCAS have been identified. To discuss these developments and refinements in the classification, we organized a Working Conference comprised of experts from Europe and the United States in August 2020. This article reports on outcomes from this conference. Of particular note, we propose adjustments in the classification of CM and SM, refinements in diagnostic criteria of SM variants, including smoldering SM and BM mastocytosis (BMM), and updated criteria for MCAS and other conditions involving MC. CD30 expression in MC now qualifies as a minor SM criterion, and BMM is now defined by SM criteria, absence of skin lesions and absence of B- and C-findings. A basal serum tryptase level exceeding 20 ng/mL remains a minor SM criterion, with recognition that hereditary alpha-tryptasemia and various myeloid neoplasms may also cause elevations in tryptase. Our updated proposal will support diagnostic evaluations and prognostication in daily practice and the conduct of clinical trials in MC disorders.
Immune‐mediated necrotizing myopathy: Unusual presentations of a treatable disease
Nicolau, Stefan , Milone, Margherita , Tracy, Jennifer A., Mills, John R. , Triplett, James , Liewluck, Teerin , Triplett, James D, Liewluck, T , Nicolau, Stefan , Triplett, James D

Mayo Clinic

Muscle & Nerve | October 8, 2021 | Volume: 64 | Issue: 6 | Pages: 734-739

10.1002/mus.27435 | PMID 34617293 Get It

AbstractIntroduction/AimsImmune‐mediated necrotizing myopathy (IMNM) is an immune‐mediated myopathy typically presenting with progressive subacute weakness and characteristic, but nonspecific, myopathological findings. Atypical cases however can mimic other inherited or acquired myopathies, depriving patients of treatment. We describe a cohort of such patients.MethodsWe retrospectively identified IMNM patients who either previously carried a diagnosis of an inherited myopathy established on clinicopathological grounds or whose muscle biopsies displayed atypical features suggestive of a different myopathy.ResultsAmong 131 IMNM patients, seven previously unreported patients (5%) met one of the above criteria. Three patients were diagnosed with limb‐girdle muscular dystrophy on the basis of a chronic progressive course of weakness and family history of myopathy or cardiomyopathy. The other four patients displayed atypical histological features (two prominent mitochondrial abnormalities, one myofibrillar pathology, and one granulomatous inflammation). Immunostaining of biopsies from 12 additional IMNM patients did not identify myofibrillar pathology. The patient with granulomatous inflammation was known to have pulmonary sarcoidosis. Genetic testing for inherited myopathies was unrevealing. Antibodies against 3‐hydroxy‐3‐methylglutaryl‐CoA reductase or signal recognition particle were identified in 5 and 1 patients, respectively. Four patients presented with slowly progressive weakness over 3–13 y, while weakness was subacute over ≤6 mo in three patients. All patients responded to immunomodulatory therapy.DiscussionAtypical clinical and histological features can occur in IMNM patients, causing delays in diagnosis and treatment. Clinicians should, therefore, consider IMNM in the differential diagnosis of unexplained proximal myopathies in spite of atypical clinical and myopathological findings.
Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients
Johnstone, Jennie , Meade, Maureen O. , Lauzier, François, Duan, Erick , Dionne, Joanna C. , Heels‐Ansdell, Diane , Thabane, Lehana , Lamarche, Daphnée , Zytaruk, Nicole , Mehta, Sangeeta , Dodek, Peter , McIntyre, Lauralyn , Karachi, Tim , Henderson, William R. , Wood, Gordon , Ovakim, Daniel , Herridge, Margaret S. , Granton, John , Wilcox, M. Elizabeth , Goffi, Alberto , Niven, Daniel J. , Lamontagne, François , D’Aragon, Frédérick , St.-Arnaud, Charles, Ball, Ian, Nagpal, Dave , Girard, Martin , Aslanian, Pierre, Charbonney, Emmanuel , Sligl, Wendy , Adhikari, Neill K. J. , Marquis, François, Archambault, Patrick , Khwaja, Kosar , Kristof, Arnold S. , Kutsogiannis, James, Paunovic, Bojan, Reeve, Brenda , Lellouche, François , Hosek, Paul, Tsang, Jennifer , Binnie, Alexandra , Trop, Sébastien, Loubani, Osama , Hall, Richard , Cirone, Robert, Reynolds, Steve, Lysecki, Paul, Golan, Eyal, Cartin‐Ceba, Rodrigo , Cook, Deborah, Group, Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials, Wallace, Christine, Sobhi, Gita, Johnstone, Jennie, Lauzier, François, Cook, Deborah, Centoanti, John, Lamarche, Daphne, Laupacis, Andreas, Roberts, Robin, Brun‐Buisson, Christian , Reynolds, Steve, Willems, Sue, Sekhon, Tina , Dodek, Peter, Ayas, Najib , Agda, Maria, Alcuaz, Victoria, Ashley, Betty-Jean, Brewer, Kelsey, Palmer, Janice L. , Brown, Glen, Pavan, Mara, Greisdale, Donald, Foster, Denise , Logie, Suzie, Yip, Judy, Auld, F. C., Carney, Gayle, FLEMING, R.Y. Declan, Good, Jennifer, Manhas, Mandeep, Boyd, Karin, Dheere, Jane, Stelfox, Tom, Couillard, Philippe , Doig, Christopher J. , Booth, Joshua , Codan, Cassidy, Ruddell, Stacy, Cameron, C. Blake, Edison, Rhonda, Mina, Breanna, Berthiaume, Luc , Gaudet, Jonathan, Kutsiogiannis, Jim, Chowdhury, Raiyan, Davidow, Jon, Johnston, Curt, Johnston, Richard , Macala, Kim, Marcushamer, Sam, Markland, D., Matheson, Doug, Payton-Gay, Damian, Zygun, David, Hewer, Tayne, Thompson, Pat, Ge, Maggie, Hall, Janny, Matenchuk, Sharon, Baig, Nadia, McCoshen, Lorena, Alexandropoulos, Katrina, Bain, Sherri, Brandt, Michelle , Constable, Cathy, Douglas, K., Maharaj, Shaleen, Travers, Sabrina, Zarychanski, Ryan, Lys, Justin, Marten, Nicole, Bhairo, Audrey, Ferenes, Halyna, Kozak, Beata, Verrier, Debra, McLaughlin, Dawn-Lee, Blouw, Marcus , Smith, Heather , Gutieror, Oliver, Wingfield, Sherri Lynn, Boyle, M A, Hrabi, Debbie, MacDonald, Chantal, Bento, Karen, Davis, Megan , Dechert, William , Longo, Barbara, Mullen, Courtney, Skrzpek, Elysia, Wierenga, Laurenne, Abuzaiter, Wesam, Amorim, Lynda, Bauer, Rosemarie, Damota, Rachel, Ho, Hoang, Macdougall, Nicole, Thornewell, Mary, Tran, Lara , Visocchi, Jennifer, Hosek, Paul, Plaxton, Bill, Armstong, Catherine, Ellis, Janelle, Fisk, Kayla, Gabnouri, Melissa, Gordon, Emilie, Haegens, Rebecca, Halford, Lisa, Hillis, Brooklyn, Jesso, Rebecca, McLaren, Jennifer , McMillan, Elliot, Pelkmans, Mariska, Rekman, Matthew, Sinkovitis, Sylvia, Truong, Monica, White, Michelle C. , Bates, Noah, Bryden-Cromwell, Susan, Cameron, Colleen, Deen, A. Gamal El, DiGiovanni, Sheri, Foss, Anders, Lee, E. H. , MacGregor, Heidi, Galbraith, Esther, McArthur, Robyn, Mcgregor, J., Miller, Keith R. , Morris, Sharon, Parker, Shelley, Smith, Candice A. , Stoglow, Joanna, Tung, Jennifer , Vos, Melissa , Hand, Lori, Klotz, Lisa, Sabev, Alexandra, Savija, Nevena , Guyatt, Paige, Cosentino, Deanna, Lourenco, Diane, Misina, Julie, Berlingieri, Joseph, Skitch, Steven , Campbell, Tracy , Basheer, Hala, Bruder, Kathy, Cheng, Jane, Qureshi, Kaiser, Infantino, C. A. González, Karachi, Timothy, Alghuroba, Mashari, Khaled, Alia , Millen, Tina, Vaisler, Ryan, Biljan, Maya, Cosentino, Deane, Marriott, Brittany, Muscedere, John, Boyd, Gordon, D`Arsigny, Christine, Drover, John, Erb, Jason , Parker, Chris M., Sibley, Stephanie , Boyd, Tracy, Georgescu, Ilinca, Hunt, Miranda , Muscedere, D., Baker, Cathy, Engel, Jennifer, Fleming, Jennifer , Roderick, Lisa, Silk, Shelley, Spencer, Marcy, Tryon, Michelle, Nagpal, Dave, Ball, Ian, Sharpe, Michael D., Bentall, Tracey, Sturt-Smith, Jessica, Ellis, T.M., Muylaert, Mindy, Paczkowski, Cindy, Campbell, Eileen, Imervoski, Susie, Ovsenek, Athena, Rondinelli, Rebecca, Longfield, Teresa, Moyer, Amy, Norris, F. H., Sumpton, Janice, Teterycz, Karina, Lapinsky, Stephen E. , Munshi, Laveena, Brown, Maedean, Giacomino, Brittany, Jakab, Marnie, Kraguiljac, Alan, Shah, Sumesh, Tamberg, E., Cheng, Doret, Han, Andrew , Leung, Holly, Mantas, Ioanna, Rodrigues, Hilary, Wyllie, Andew, Carmargo, Mercedes, Richter, Beverly, Caporuscio, Rita, Falvo, Rachel Kressner, Fleming, Dimitra, Maxwell, Carmelina, Plantic, Karmen, McIntyre, Lauralyn, Pagliarello, Giuseppe, D`Egidio, Gianni, English, Shane, Hartwick, Mike, Hooper, Jonathan C., Kubelik, D., Meggison, Hilary , Patel, Rakesh , Po, Joseph, Rosenberg, Erin, Gomes, Brigette, Leclair, Lianne, Porteous, Rebecca , Reddie, Shawna, Watpool, Irene , Cox, Marianne, Fraser, Kathy, Kuhn, Jennifer, Richard, Susanne, Weir, Sherry, Cardinal, Pierre , Jones, Gwynne, Microys, Sherissa, Sarti, Aimee , Seely, Andrew , Acres, Shelley, Mietitis, Sydney, Montroy, Kaitlyn, Aikens, Wendy, Dugal, Anne-Marie, Soth, Mark, Alhazanni, Waleed, Clarke, France, Copland, Mary, Hoad, Neala, Sheers, M., Takaoka, Alyson, Zytaruk, Nicole, Connolly, Christa, Davis, Denise, Gallinas, Tracy, Lee-Yoo, Jean, Lukinuk, Connie, Musielak, Leia, Pavunkovic, Nancy, Pelayo, Joy, Phillips, Kaitlyn , Pracsovics, Catherine, Raimondo, Julia, Stankus, Vida, Wright, Angela, Young, Crystal , Cirrone, Rob, Kavikondala, Kanthi, Pellerin, Axelle, Tomat, Laura, Carter, Jeff , Jani, J., Yaets, Brendan, Hodder, Jennifer, Khalid, Imrana, Lee, Julie , Salway, Kurtis D., Sandhu, Gyan, Santos, Marlene, Smith, Orla, Wang, Melissa, Dewhurst, Norman, Dowbenka, Ann, Kosinski, Ann, Parsons, Laura, Proceviat, J, Ramonas, Gitana, Yuen, Mae, Amaral, Andre , Fowler, Rob, Scales, Damon C. , Marinoff, Nicole, Pérez, Adic, Wang, Jane , Hatzifilalithis, Katrina, Iazzetta, John, Kolos, Chrys, Quinton, Ingrid, Herridge, Margaret, Archer, Jaimie, Fraser, Brooke , Geen-Smith, Cheryl, Matté, Andrea, Robles, Priscilla, Urrea, Cristian, Ascroft, Jane, Haji, Fatima , Ming, Jie , Suen, Matthew , Walid, Muhammad, Westlund, Jill M., McCredie, Victoria , Wilcox, Elizabeth , Farías, Paulina , Kosky, Barbara, Pugliese, Christina, Stenyk, Lia, Walczak, Karolina, Ae, Kyung, Kaur, Rajvinder , Lui, Jane , Mateo, Sophia, Pham, Nga, Heslegrave, Ronald J. , Panchbhaya, Zaynab, Sharman, Kim, Goel, Rakhi, Kozluk, Kim, Labelle, Julianne, Marsonia, Hina, Scott, Cecillia, Aslanian, P., Bélisle, Sylvain, Denault, André , Guimond, Jean‐Gilles, Halwagi, Antoine, Hebert, Paul L. , Kolan, Christopher, Mancebo, Jordi , Robillard, Nicholas , Benettaib, Fatna, Boumahni, Dounia, Caporuscio, Casey Bourdeau, Cantin, M, Côté-Gravel, Virginy, Ghamraoui, Ali, Lebrasseur, Martine, Courville, Lancelot Legendre, Lorio, S., Madrid, Maria Trinidad, Poitras, Nicole, Rigal, Romain, Salamé, Maya, Tran, V.K., Bacon, Katie, Boudreau, Nathalie , Carvajal, Cecilia, Gauthier, Lyne, Gendron, Julie, Jean, Karine, Laforest, Louise, Lembo, Antonietta, Lim, S. H., Pagé, France, Pelletier, L, Rodrigue, Marie-Christine, Bellemare, Jean-François, Bordeleau, Simon, Drouin, Christine, Duhaime, Benoit, Laberge, Ann, Lechance, Philippe, Deblois, Estel, Dionne, Maude, Lavoie, Lise, Michel, Isabelle, Pépin, A., Poulin, S., Anctil, Sarah, Marchand, Louis-Étienne , Roy, Robin, St-Arnaud, Charles , Quiroz, Héctor, Bérard, Dominique, Leclair, Marc-André, Bolduc, Virginie, Carbonneau, Élaine, Marchand, Joannie, Masse, Marie-Hélène , Cloutier, Sylvie , Guay, M, Morin, Line, Nicolson, J. T., Paquette, Isabelle, Théberge, France, Lamarche, Yoan , LeGuillan, Soazig, Serri, Karim , Verdant, Colin , Beaulieu, Yanick, Bellemare, Patrick, Rico, Philippe, Bernard, Françis , Giasson, Marc, Brunette, Véronique, Cavayas, Alexandros, Lévesque, Émilie, Labikova, Halina, Palacios, Julia , Langlois, Marie-Ève, Williams, Virginie, Nguyễn, Thùy Anh , Phaneuf, Valérie, Wang, Han Tin, Toupin, Francis, Ahern, Stéphane P., Laufer, Brian, Brosseau, Marc, Dul, Pauline, Harvey, Johanne, Inthanavong, Lotthida, Tassy, Danaë, Assayag, Helen, Bachand, M., Bétournay, Marysa, Daoust, Karine, Goyette, Kristine, Lessard, Ariane, Quach, Marceline, Barriault, Danny, Bellemare, David, Boivin, Anick, Breton, S., Cloutier, Ève, Daigle, Marjorie, Delisle-Thibeault, Charles, Giannakouros, Panagiota, Grenier, Stéphanie, Guilbault, Gabrielle, Léger, Caroline, Trembley, Marie-Claude, Gaudreau, Julie, Grégoire, Claire, Labbé, Véronique, Laprise-Rochette, Ariane, Ouellet, Caroline, Samson, Mélanie , Simoneau, Marie-David, Tourcotte, Virginie, Tran, Tuong-Vi, Lellouche, François, Sia, Ying Tung, Simon, Mathieu, Bouchard, Pierre-Alexandre, Lizotte, Patricia, Châteauvert, Nathalie, Grenier, T, Khwaja, Kosar, Deckelbaum, Dan, Gursahaney, Ash, Hornstein, David, Jayaraman, Dev , Razek, Tarek , Salasidis, Robert, Zanelli, Patrizia, Alam, Norine , Doerksen, Tonia, Matte, Gilbert, Robert, Marie‐France, Goldberg, Peter, Hatzakorzian, Roupen , Shahin, Jason , Qureshi, Salman, Campisi, Josie, Botan, Vasilica, Capilnean, Anissa, Corey, A. E., Gagné, Annick, Mian, J N, Normandin, Kathleen, Hall, Rick , Green, Robert, Gillis, Diana, Julien, Lisa, Magennis, Laura, Mitterer, Tamara, Arsenault, Joanna, Bruce-Payne, Kim, Gallant, Patti, Oeckler, Richard A. , Anderson, Brenda J., Liedl, Lavonne M., Meade, Laurie, Weist, Sueanne, Bartoo, Anna, Bauer, Debbie, Brickley, Vince, Bridges, S. Louis , Brunn, G.J., Eickstaedt, Jennifer E., Bergerson, Jill, Showalter, Sandy, Manley, Melissa, Taylor, Robert, Cryton, Margaret, Fowler, K. T., Krause, Katie, O`Brien, Jackie, Tow, Marianne, Ma, John, Moore, Kaitlin MS, Al‐Dawood, Abdulaziz, Tlayjeh, Haytham , Ghanem, Alaaeldien, Hassanien, Ahmad, Sharkawi, Ashraf El, Humaid, Felwa Bin, Alanizi, Hala, Alanizy, Nadyah, Bogami, Njoud Al, Muhaidib, Mohammed, Gramish, Jawaher , Alsomali, Randa, Devera, Nora, Villafranca, M.C. Muñoz, Fowler, Robert , Thabane, Lehana , Lauzier, François, Marshall, John C. , Arabi, Yaseen M. , Surette, M G , English, Shane , Rochwerg, Bram , Stelfox, Henry T. , Muscedere, John , Ball, Ian, Williamson, David R. , Friedrich, Jan O. , Kutsogiannis, Demetrios James , Zarychanski, Ryan , Taylor, Robert, Cook, Deborah, Group, Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials, Johnstone, Jennie, Lauzier, François, Cook, Deborah, Oczkowski, Simon J. W. , Bowdish, Dawn M. E. , Reynolds, Steve, Dodek, Peter, Ashley, Betty Jean, Palmer, Janice, Sekhon, Mypinder S. , Auld, Fiona, Fleming, R.Y.Declan, Stelfox, Tom, Parhar, Ken Kuljit S. , Cameron, Candice, Martin, Anne , Thompson, Pat, Bagshaw, Sean M. , Brandt, Michelle, Douglas, Kari, Zarychanski, Ryan, Valente, Maria, Olafson, Kendiss P. , Smith, Heather, Abuzaiter, Wesam, Hosek, Paul, Fisk, Kayla M., McLaren, Jennifer, White, Michelle, Deen, Aminah, Lee, Esther, McGregor, Julie, Miller, Keith, Morris, Sharon, Vos, Melissa, Belley‐Côté, Emilie P. , Shaikh, Sameer, Qureshi, Kaiser, Muscedere, John, D`Arsigny, Christine, Maslove, David M. , Fleming, Jennifer, Spencer, Marcy, Nagpal, Dave, Ball, Ian, Bosma, Karen J. , Alexander, Michelle, Norris, Faith, Munshi, Laveena , Grewal, Gagan , McIntyre, Lauralyn, D`Egidio, Gianni, English, Shane, Hooper, Jonathan, Kyeremanteng, Kwadwo , Neilipovitz, David , Cox, Marianne, Fraser, Kathy, Kuhn, Jennifer, MacLeod, Rob , Rose, Dawn, Kim, John S. , Beinum, Amanda van , Fetzer, Susan, Clarke, France J. , Sheers, Melissa, Zytaruk, Nicole, Davis, Denise, Eaton, Catherine, Lukinuk, Connie, Wright, Angela, Khalid, Imrana, Lee, Julie, Lee, Yoon Min , Cuthbertson, Brian H. , Kaur, Navjot , Herridge, Margaret, Chen, Daniel Tzu-Hsuan , Haji, Fatima, Ming, Jie, Farias, Paulina, Kaur, Rajvinder, Pham, Tam Thi , Goel, Rakhi, Carrier, François Martin , Chassé, Michaël , Hébert, Paul, Kolan, Christophe , Boumahni, Dounia, Ghamraoui, Ali, Lebrasseur, Martine, Lorio, Stéphanie, Laforest, Louise, Lim, Sothun, Morrissette, Jennifer, Pagé, France, Dionne, Maude, Michel, Isabelle, Pépin, Alexandre, Poulin, Sandrine, Cloutier, Sylvie, Nicolson, Jessie, Paquette, Isabelle, Harvey, Johanne, Inthanavong, Lotthida, Daoust, Karine, Turgeon, Alexis F , Boivin, Anick, Breton, Sarah-Judith, Ouellet, Catherine, Grégoire, Claire, Samson, Mélanie, Lellouche, François, Khwaja, Kosar, Grushka, Jeremy Richard , Garcia, Laura, Magder, Sheldon A. , Corey, Alyssa, Mian, Jasmine, Hall, Rick, Green, Robert, Gillis, Diana, Anderson, Brenda, Brunn, Greg, Stern, Erin, Taylor, Robert, Fowler, Kim, Krause, Katie, Moore, Kaitlin , Ghanem, Alaaeldien, Hegazy, Mohamed I. , Villafranca, Marjane

Mayo Clinic

JAMA | September 21, 2021 | Volume: 326 | Issue: 11 | Pages: 1024

10.1001/jama.2021.13355 | PMID 34546300 Get It

Benzodiazepine administration patterns before escalation to second‐line medications in pediatric refractory convulsive status epilepticus
Sheehan, Theodore , Amengual‐Gual, Marta , Vasquez, Alejandra , Abend, Nicholas S. , Anderson, Anne E. , Arya, Ravindra , Aguilar, Cristina Barcia , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Gaínza‐Lein, Marina , Goldstein, Joshua , Goodkin, Howard P. , Huh, Linda , Jackson, Michele , Kahoud, Robert J., McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Reece, Latania, Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Shellhaas, Renée A. , Smith, Garnett , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Zhang, Bo , Arya, Ravindra , Barcia Aguilar, Cristina , Farias-Moeller, Raquel , Gaillard, William D , Gaínza-Lein, Marina , Guerriero, Rejean M , Kahoud, Robert, Lai, Yi-Chen , Mikati, Mohamad A , Morgan, Lindsey A , Novotny, Edward J , Sands, Tristan T , Shellhaas, Renée A , Loddenkemper, Tobias , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Sheehan, Theodore , Appavu, Brian , Glauser, Tracy A. , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Epilepsia | August 21, 2021 | Volume: 62 | Issue: 11 | Pages: 2766-2777

10.1111/epi.17043 | PMID 34418087 Get It

Abstract Objective This study was undertaken to evaluate benzodiazepine (BZD) administration patterns before transitioning to non‐BZD antiseizure medication (ASM) in pediatric patients with refractory convulsive status epilepticus (rSE). Methods This retrospective multicenter study in the United States and Canada used prospectively collected observational data from children admitted with rSE between 2011 and 2020. Outcome variables were the number of BZDs given before the first non‐BZD ASM, and the number of BZDs administered after 30 and 45 min from seizure onset and before escalating to non‐BZD ASM. Results We included 293 patients with a median (interquartile range) age of 3.8 (1.3–9.3) years. Thirty‐six percent received more than two BZDs before escalating, and the later the treatment initiation was after seizure onset, the less likely patients were to receive multiple BZD doses before transitioning (incidence rate ratio [IRR] = .998, 95% confidence interval [CI] = .997–.999 per minute, p = .01). Patients received BZDs beyond 30 and 45 min in 57.3% and 44.0% of cases, respectively. Patients with out‐of‐hospital seizure onset were more likely to receive more doses of BZDs beyond 30 min (IRR = 2.43, 95% CI = 1.73–3.46, p < .0001) and beyond 45 min (IRR = 3.75, 95% CI = 2.40–6.03, p < .0001) compared to patients with in‐hospital seizure onset. Intermittent SE was a risk factor for more BZDs administered beyond 45 min compared to continuous SE (IRR = 1.44, 95% CI = 1.01–2.06, p = .04). Forty‐seven percent of patients ( n = 94) with out‐of‐hospital onset did not receive treatment before hospital arrival. Among patients with out‐of‐hospital onset who received at least two BZDs before hospital arrival ( n = 54), 48.1% received additional BZDs at hospital arrival. Significance Failure to escalate from BZDs to non‐BZD ASMs occurs mainly in out‐of‐hospital rSE onset. Delays in the implementation of medical guidelines may be reduced by initiating treatment before hospital arrival and facilitating a transition to non‐BZD ASMs after two BZD doses during handoffs between prehospital and in‐hospital settings.
Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Anderson, Clarke, Cook, Shelly, Gow, Kenneth W. , Hiniker, Susan M. , Jasty‐Rao, Rama, Lin, Chi , Lovvorn, Harold N. , MacEwan, Iain, Martínez-Agosto, Julián A. , Mullen, Elizabeth A. , Murphy, Erin S. , Ranalli, Mark , Rhee, Daniel S. , Tracy, Elisabeth T. , Vern-Gross, T.Z., Walsh, Michael F. , Wickiser, Jonathan E., Zapala, Matthew A. , Berardi, Ryan A., Hughes, Miranda, Vern-Gross, Tamara, Tracy, Elisabeth T , Balis, Frank M. , Green, Daniel M. , Dhillon, Jasreman , Rokitka, Denise A. , Walz, Amy L.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 20, 2021 | Volume: 19 | Issue: 8 | Pages: 945-977

10.6004/jnccn.2021.0037 | PMID 34416707 Get It

The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
Ganesh, Ravindra , Bierle, Dennis M. , Anderson, Ryan J. , Arndt, Lori L., Arndt, Richard , Culbertson, Tracy L, Borgen, Molly J. Destro, Hanson, Sara N. , Kennedy, Brian , Kottke, Brian B, Larsen, Jennifer J., Ramar, Priya , Rosedahl, Jordan K., Seville, Maria Teresa , Speicher, Leigh L. , Tulledge‐Scheitel, Sidna M. , Wilker, Caroline G. , Arndt, Richard F, Destro Borgen, Molly J, Kennedy, Brian D, Tulledge-Scheitel, Sidna M, Razonable, Raymund R , Ganesh, Ravindra , Philpot, Lindsey M. , Razonable, Raymund R.

Mayo Clinic

The Journal of Infectious Diseases | July 17, 2021 | Volume: 224 | Issue: 8 | Pages: 1278-1286

10.1093/infdis/jiab377 | PMID 34279629 Get It

Abstract Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the outcomes of patients who received these therapies to identify factors associated with hospitalization and other clinical outcomes. Methods Adult patients who received monoclonal antibody from 19 November 2020 to 11 February 2021 were selected and divided into those who received bamlanivimab (n = 2747) and casirivimab-imdevimab (n = 849). The 28-day all-cause and COVID-19–related hospitalizations were compared between the groups. Results The population included 3596 patients; the median age was 62 years, and 50% were female. All had ≥1 medical comorbidity; 55% had multiple comorbidities. All-cause and COVID-19–related hospitalization rates at 28 days were 3.98% and 2.56%, respectively. After adjusting for medical comorbidities, there was no significant difference in all-cause and COVID-19–related hospitalization rates between bamlanivimab and casirivimab-imdevimab (adjusted hazard ratios [95% confidence interval], 1.4 [.9–2.2] and 1.6 [.8–2.7], respectively). Chronic kidney, respiratory and cardiovascular diseases, and immunocompromised status were associated with higher likelihood of hospitalization. Conclusions This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.
Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report
Johnson, Skyler B. , Parsons, Matthew, Dorff, Tanya B. , Moran, Meena S. , Akerley, Wallace , Bauman, Jessica R. , Spratt, Daniel E. , Bylund, Carma L. , Swire‐Thompson, Briony , Scherer, Laura D. , Spratt, Daniel E , Parsons, Matthew, Ward, John Headley , Cohen, Stacey A. , Hubbard, Joleen M. , Onega, Tracy , Tward, Jonathan D. , Fagerlin, Angela

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 14, 2021 | Volume: 114 | Issue: 7 | Pages: 1036-1039

10.1093/jnci/djab141 | PMID 34291289 Get It

Abstract There are few data on the quality of cancer treatment information available on social media. Here, we quantify the accuracy of cancer treatment information on social media and its potential for harm. Two cancer experts reviewed 50 of the most popular social media articles on each of the 4 most common cancers. The proportion of misinformation and potential for harm were reported for all 200 articles and their association with the number of social media engagements using a 2-sample Wilcoxon rank-sum test. All statistical tests were 2-sided. Of 200 total articles, 32.5% (n = 65) contained misinformation and 30.5% (n = 61) contained harmful information. Among articles containing misinformation, 76.9% (50 of 65) contained harmful information. The median number of engagements for articles with misinformation was greater than factual articles (median [interquartile range] = 2300 [1200-4700] vs 1600 [819-4700], P = .05). The median number of engagements for articles with harmful information was statistically significantly greater than safe articles (median [interquartile range] = 2300 [1400-4700] vs 1500 [810-4700], P = .007).
Factors associated with long‐term outcomes in pediatric refractory status epilepticus
Gaínza‐Lein, Marina , Aguilar, Cristina Barcia , Piantino, Juan , Chapman, Kevin , Fernández, Iván Sánchez , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Brenton, J. Nicholas , Carpenter, Jessica L. , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , Huh, Linda , Kahoud, Robert J., McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Nayak, Anuranjita , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Reece, Latania, Riviello, James J. , Sannagowdara, Kumar , Sands, Tristan T. , Sheehan, Theodore , Tasker, Robert C. , Vasquez, Alejandra , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Zhang, Bo , Barcia Aguilar, Cristina , Sánchez Fernández, Iván , Arya, Ravindra , Farias-Moeller, Raquel , Gaillard, William D , Kahoud, Robert, Lai, Yi-Chen , Mikati, Mohamad A , Morgan, Lindsey A , Novotny, Edward J , Sands, Tristan T , Sheehan, Theodore , Loddenkemper, Tobias , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Appavu, Brian , Glauser, Tracy A. , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Epilepsia | July 12, 2021 | Volume: 62 | Issue: 9 | Pages: 2190-2204

10.1111/epi.16984 | PMID 34251039 Get It

AbstractObjectiveThis study was undertaken to describe long‐term clinical and developmental outcomes in pediatric refractory status epilepticus (RSE) and identify factors associated with new neurological deficits after RSE.MethodsWe performed retrospective analyses of prospectively collected observational data from June 2011 to March 2020 on pediatric patients with RSE. We analyzed clinical outcomes from at least 30 days after RSE and, in a subanalysis, we assessed developmental outcomes and evaluated risk factors in previously normally developed patients.ResultsFollow‐up data on outcomes were available in 276 patients (56.5% males). The median (interquartile range [IQR]) follow‐up duration was 1.6 (.9–2.7) years. The in‐hospital mortality rate was 4% (16/403 patients), and 15 (5.4%) patients had died after hospital discharge. One hundred sixty‐six (62.9%) patients had subsequent unprovoked seizures, and 44 (16.9%) patients had a repeated RSE episode. Among 116 patients with normal development before RSE, 42 of 107 (39.3%) patients with available data had new neurological deficits (cognitive, behavioral, or motor). Patients with new deficits had longer median (IQR) electroclinical RSE duration than patients without new deficits (10.3 [2.1–134.5] h vs. 4 [1.6–16] h, p = .011, adjusted odds ratio = 1.003, 95% confidence interval = 1.0008–1.0069, p = .027). The proportion of patients with an unfavorable functional outcome (Glasgow Outcome Scale‐Extended score ≥ 4) was 22 of 90 (24.4%), and they were more likely to have received a continuous infusion.SignificanceAbout one third of patients without prior epilepsy developed recurrent unprovoked seizures after the RSE episode. In previously normally developing patients, 39% presented with new deficits during follow‐up, with longer electroclinical RSE duration as a predictor.